Published in final edited form as:

Free Radic Res. 2009 February ; 43(2): 106–116. doi:10.1080/10715760802616676.

Sarcolipin and ubiquitin carboxy-terminal hydrolase 1 mRNAs are over-expressed in skeletal muscles of α -tocopherol deficient mice

Vihas T. Vasu, Sean Ott, Brad Hobson, Vania Rashidi, Saji Oommen, Carroll E. Cross, and Kishorchandra Gohil

Department of Internal Medicine, Genome and Biomedical Sciences Facility, University of California, Davis, CA 95616, USA

Abstract

The transcriptome of ataxic muscles from α -tocopherol transfer protein deficient (ATTP-KO), 23-month old, mice was compared with that of their normal littermates. Genes encoding sarcolipin (*sln*) and ubiquitin carboxyl-terminal hydrolase (*uchl1*) were over-expressed (≥ 10 -fold) in ataxic muscles. SLN is a 3.2 kDa membrane protein that binds to sarcoplasmic reticulum calcium ATPase, regulates Ca^{++} transport and muscle relaxation–contraction cycles. UCHL1 is a 24.8 kDa member of proteasome proteins; it is over-expressed in myofibrillar myopathy and is associated with neurodegenerative diseases. Furthermore, six additional transcripts, three encoding thin-filament proteins and three encoding Ca^{++} sensing proteins that participate in contraction-relaxation cycle, and eight transcripts that encode members of lysosomal proteins were also over-expressed in ataxic muscles. These observations suggest that chronic α -tocopherol (AT) deficiency activates critical genes of muscle contractility and protein degradation pathways, simultaneously. The magnitude of induction of *sln* and *uchl1* was lower in asymptomatic, 8-month old, ATTP-KO mice and in 8-month old mice fed an AT-depleted diet. These studies suggest *sln* and *uchl1* genes as novel targets of AT deficiency and may offer molecular correlates of well documented descriptions of neuromuscular dysfunctions in AT-deficient rodents. Since the neuromuscular deficits of ATTP-KO mice appear to be similar to those of patients with ATTP mutations, it is suggested that over-expression of *sln* and *uchl1* may also contribute to AT-sensitive ataxia in humans.

Keywords

Ataxia; AVED; calcium homeostasis; muscle relaxation; myopathy; tocopherol transfer protein; ubiquitin; vitamin E

Introduction

α -Tocopherol transfer protein (ATTP) is a ~32 kDa protein that selects α -tocopherol (AT) from seven other members of the dietary vitamin E family and preferentially transfers AT to lipoproteins secreted by the liver [1]. ATTP is abundantly expressed in liver [2–4], but its expression is low or undetectable in peripheral organs and various regions of the central nervous system [5]. Therefore, hepatic ATTP is a major determinant of blood and tissue concentrations of AT [6,7]. The physiological importance of ATTP and AT is underscored by the discovery of several mutations in *attp* gene in patients displaying ataxia with vitamin E deficiency, AVED

Correspondence: Kishorchandra Gohil, Genome and Biomedical Sciences Facility, Suite 6510, Department of Internal Medicine, University of California, Davis, CA 95616, USA. Tel: 530 754 6932. Fax: 530 752 8632. kgohil@ucdavis.edu.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.

[8,9]. Although progressive neuromuscular disease associated with vitamin E deficiency in patients with AVED or abetalipoproteinaemia or chronic cholestasis [10,11] is well documented, the identity of the genes that may contribute to the failure of the neuromuscular system remain to be clarified.

The development of transgenic mice that recapitulate the systemic AT-deficiency and neuromuscular phenotypes of AVED patients with *attp* mutations offer a useful model to investigate mechanisms of actions of AT *in vivo* [12–17]. Most studies of the genetic model of AT-deficiency (ATTP-KO mice) have focused on defining AT-dependent changes in the central nervous system, which is severely depleted in AT [5,12] in spite of the mice consuming a diet containing sufficient AT to maintain normal fertility. For example, somatosensory evoked potentials in the cerebral cortex of 18–20 month old ATTP-KO mice were shown to be markedly attenuated when compared to those recorded from WT mice [14]. This observation may be attributed to low expression of genes encoding synaptic and calcium regulatory proteins in the cerebral cortex of ATTP-KO mice [12,18].

Muscles and various regions of the brains of ATTP-KO mice are severely AT-depleted, possibly from birth, compared to their WT littermates, in spite of consuming a diet that contains sufficient AT for fertility [5,19]. An earlier study described atrophic muscle fibres in 20-month old ATTP-KO, but not in the muscles of 12-month old ATTP-KO, ataxic mice [14]. These observations suggest that histological changes appear after the initiation of ataxia. More comprehensive descriptions of muscle fibre necrosis, decrease in cytochrome oxidase activity and ‘a waddling ataxic gait’ has also been described in ~1-year old rats that consumed an AT-depleted diet, post-weaning [20]. However, temporal changes in the activity of muscle genome imposed by chronic AT-deficiency are less well characterized. A previous study addressed temporal changes in muscle gene expression during ~1-year of AT-deficiency, imposed by an AT-deficient diet, that did not produce obvious neuromuscular deficits [21].

We hypothesized that simultaneous changes in the transcription of distinct sets of multiple, functionally-related, genes are likely to play an important role in the emergence and persistence of the ataxic phenotype that occurs late during chronic AT-deficiency. The present study aimed at identifying the possible contribution of ~8500 muscle genes in the pathogenesis of ataxia, defined by shorter stride lengths of ‘old’, 23-month, ATTP-KO mice [14,18] compared to their normal littermates. In addition, some of the most responsive AT-sensitive genes identified in ‘old’ ataxic mice were also assayed in asymptomatic, ‘adult’, 8-month mice to define separately the contribution of age and AT-deficiency obtained by either the deletion of the ATTP-gene or by feeding an AT-depleted diet.

Materials and methods

Diets and mice

The AT-depleted and AT-sufficient (35 IU tocopheryl acetate/Kg diet) diets used in this study were prepared as previously described [22,23]. Mice were allowed to access food and water *ad libitum*.

All the experiments in mice were humanely conducted and approved by Institutional Animal Care and Use Committee, University of California, Davis. Male mice from our colony of WT and ATTP-KO mice were studied [5]. Eight-month old ‘adult’ mice (six WT mice and four ATTP-KO mice) and 22–23 month old, ‘old’, mice (five WT mice and four ATTP-KO) were used for these studies. The group of mice assigned for 8 month study included six WT mice which were randomly sub-grouped to be fed either the AT-depleted ($n=3$) or the AT-sufficient ($n=3$) diets.

Skeletal muscle collection and processing

Mice were anaesthetized with intraperitoneal injection of pentobarbital (120 mg/Kg). After collection of blood by cardiac puncture, quadriceps and gastrocnemius muscles were exposed, dissected and immediately frozen in dry-ice. The frozen samples were stored at -80°C .

RNA extraction and sample preparation for GeneChip and qRT-PCR analysis

Frozen quadriceps and gastrocnemius muscles from each mouse were pulverized in pre-frozen porcelain mortar and pestle (in dry ice) to obtain finely powdered frozen muscle which was transferred to a 2.0 ml conical glass-teflon homogenizer. RNA was extracted with PARISTM protein and RNA isolation kit essentially as described by the manufacturer (Applied Biosystems, Foster City, CA). Total RNA was quantified spectrophotometrically.

GeneChip (Mouse Genome 430 A 2.0) analysis was performed as previously described [24], using four GeneChips. A 5 μg aliquot of each of the four total RNA extracts (two extracts from WT-muscles and two extracts from ATTP-KO muscles) were processed. The scanned GeneChip images were processed to obtain hybridization signal intensities as described in Affymetrix GeneChip Operating System, V 1.4 (Affymetrix, Santa Clara, CA). To obtain the list of genes that were differentially expressed between the ATTP-KO and the WT mice, the '.cel' files were imported into dChip software (1.0.01). The data were normalized and processed to obtain differentially expressed genes with default settings [25]. The data from WT-mice were used as baseline and those from the ATTP-KO mice were used as experimental to obtain fold-changes. The list of genes with fold-changes was then edited to exclude all the genes that showed less than 2-fold change and those that did not have annotations. The data were tabulated to show gene names, their fold-change attributed to ATTP-KO genotype, Affymetrix probe set identifiers and gene number in mouse genome database. The Affymetrix probe set identifiers offer an opportunity to identify, from the Affymetrix Database, the precise deoxynucleotide sequences of probes used in the Mouse genome 430 A 2.0 GeneChips and for designing oligonucleotide primers for quantitative PCR verifications.

Quantitative real-time PCR (qRT-PCR) was performed as previously described [22]. Nineteen aliquots of cDNAs synthesized from muscle RNA extracts from 19 different mice were used for validation of the selected genes identified by the GeneChip assay. The selection criterion was based of their relevance to the novel findings of this study. The oligonucleotide sequences of primer pairs were obtained using Primer Express software (Applied Biosystems) and their sequences are shown in Table I.

Statistics

The means, standard error of means (SEMs) and significance of difference (p -values) in fold-change determined by qRT-PCR were calculated by t -test using GraphPad Prism software 4.0 (La Jolla, CA).

Results

The analytical strategy included confirmation of genotype of the mice (Figure 1), obtaining the primary list of AT-sensitive genes (and their functional assignments) from muscles of 23-month old ataxic mice (Table II), confirmation of the selected genes by qRT-PCR (Table III) and assaying the AT-sensitive, qRT-PCR confirmed genes in the AT-deficient muscles of 8-month old mice (Table IV).

Confirmations of ATTP-KO and WT genotypes

Figure 1 shows that the expression of ATTP mRNA in muscles of 2-year old ataxic mice, assayed by either GeneChips or qRT-PCR, is below the limits of detection. In contrast, ATTP

mRNA expression is robust (similar to that of GAPDH as indicated by the ratio of 1) in WT, 2-year old, male mice and is very low in ATTP-KO mice, as expected. A previous study has shown that the muscles and other tissues of ATTP-KO mice are deficient in AT [19].

AT-sensitive muscle transcriptomes

To determine the genome-wide signature of mRNA changes associated with chronic AT-deficiency and the resulting ataxic phenotype, muscle RNA extracts from 'old' WT and ATTP-KO mice were processed. The GeneChip assay detected ~12 000 mRNAs in muscles. Comparison of ATTP-KO- with that of WT-muscle transcriptomes identified 57 genes that were differentially expressed (≥ 2 -fold and the difference in signal intensity for each gene between the two data sets was ≥ 100 units) (Table II). Fifty-three genes were over-expressed in ATTP-KO compared with WT-muscles. These genes were then clustered according to their functions and literature descriptions. Six groups of genes each including 4–7 genes were obtained (Table II). Thirteen genes could not be assigned to any of the six clusters and are listed as miscellaneous in Table II. The functional groups included genes that encode: cytoskeletal and calcium sensing-regulated proteins, those that participate in protein degradation, immune-inflammation, thiol-oxidation and metabolic stress, vesicular and secretory functions and those associated with mitochondria.

Over-expression of genes that affect Ca^{++} mediated muscle contraction-relaxation cycles

A cluster of four-genes (sarcolipin (*sln*), troponin I (*tnni*), troponin C (*tnnc*) and calsequestrin 2 (*casq2*)), whose encoded proteins are known to participate in Ca^{++} dependent muscle contraction and relaxation cycles, were over-expressed in muscles of ATTP-KO compared with WT littermate mice (Table II). There was a 14-fold induction of *sln*, the gene encoding SLN, a 3.6 kDa protein [26] that inhibits re-uptake of sarcoplasmic calcium by inhibiting the activity of ATPase, Ca^{++} transporting 2, also known as SER-CA2A2 [27]. Gene encoding a target of SLN, SERCA2A2 was also induced. Table II also shows a 2-fold induction of the gene that encodes calsequestrin 2, the main Ca^{++} buffer of sarcoplasmic reticulum [28]. At least three additional genes that regulate calcium-dependent contraction-relaxation cycles of skeletal muscles were also co-activated with *sln* (Table II). Coordinated inductions of *tnni*, *tnnci* and *tpm3* are particularly remarkable because the encoded proteins form the thin filaments of striated muscles and they have been suggested to form an inhibitory unit that prevents interactions between actin and myosin [29] and, thereby, may modulate muscle relaxation and contraction cycles. This cluster of seven genes is designated hereafter as 'the sarcolipin cluster'.

Activation of proteolytic and inflammatory responses by chronic AT-deficiency

Genes associated with proteolysis were over-expressed in ataxic, AT-deficient muscles (Table II). Many of the genes in this cluster (e.g. cathepsins B, L and S) are associated with lysosomes and phagosomes [30]. Three genes encoding members of the ubiquitin-dependent proteosomal pathway (some of which are associated with processing by phagosomes [31]) are also included in this cluster.

Ataxic muscles of ATTP-KO mice also displayed markers of overactive inflammatory response (Table II). Inductions of genes encoding members of major histocompatibility class II and beta-2 microglobulin are included in one group for their roles in immune functions that depend on ubiquitin-proteosomal pathways [31,32]. Co-inductions of CD36 and apolipoproteins D and E genes are noteworthy because they participate in lipoprotein metabolism and are frequently implicated in inflammatory responses [33,34]; CD36 is a receptor for oxidized low density lipoproteins and apolipoproteins are integral components of these macromolecular complexes. A 3-fold induction of gene encoding cytochrome P4502e1 in the ATTP-KO muscles is further suggestive of increased oxidation of lipids and of proteins which may be targeted to proteosome complexes [35,36] in AT-deficient muscles.

QRT-PCR assay of selected genes validates GeneChip data

To address the possible relation between the ataxic phenotype and mRNA expression, we focused on genes that have previously been associated with muscle contraction-relaxation cycles and muscle protein degradation (Table III). The induction and repression of all the genes selected from the list of 57 differentially expressed genes, identified by the GeneChip assay, were confirmed by qRT-PCR assay of the same RNA samples used for the GeneChip assay (Table III). The precise magnitude of the change obtained by the two methods differed; for example, the GeneChip assay underestimated *sln* induction, compared to that obtained by qRT-PCR assay (Table III). Furthermore, muscle RNA extracts from additional 'old' mice ($n=5$, three WT mice and two ATTP-KO mice) also showed the predicted change in the expression of the same genes (Table III). Hence, qRT-PCR validation assays for the expression of genes identified by the GeneChip assay attest to the reliability and reproducibility of the analytical procedures used for the genome-wide analysis of muscle mRNAs and the initial analytical step in the search for AT-sensitive genes in ataxic muscles.

Effect of age and dietary AT-deficiency on the sarcolipin gene cluster

The contribution of age on the expression of the sarcolipin gene cluster, implicated in the regulation of muscle contraction-relaxation cycle, was assayed in muscles from 'adult' WT and ATTP-KO mice and in adult mice fed the AT-depleted diet. A 6-fold-induction of *sln* was detected in the ATTP-KO mice when compared to the expression of *sln* in muscles from WT mice (Table IV). Furthermore, when WT mice were fed the AT-depleted diet, muscle *sln* was also induced (Table IV). Thus, data from three different groups of mice of two different genotypes demonstrate that muscle *sln* expression is a sensitive indicator of AT-deficiency. Moreover, *sln* is the most responsive AT-sensitive gene within the *sln* cluster, in muscles of both 'adult' and 'old' mice (Table IV).

Two genes, one encoding TROPONIN I and the other encoding calcium transporting ATPase2a2 (also known as SERCA2a2), appear to be more sensitive to diet-induced AT-deficiency compared to deficiency resulting from the deletion of the ATTP-gene. Data in Table IV also suggest differential sensitivity of each gene within the *sln* cluster to AT-deficiency. For example, the large induction of troponin C1 (*tnnc1*) and that of tropomyosin 3, gamma (*tpm3*) is seen only in the muscles of 'old' ATTP-KO mice.

Effect of age and dietary AT-deficiency on the uchl1-gene cluster

Four of the nine genes in *uchl1* gene cluster were selected for qRT-PCR verification in 'adult' and 'old' muscles (Table IV). Expression of three of the four genes in this cluster was lower in muscles of 'adult' ATTP-KO compared with 'old' ATTP-KO mice. The expression of *uchl1* was activated, 4.2- and 7.6-fold, by AT deficiency obtained by AT-deficient diet and by the deletion of ATTP gene, respectively; both these inductions were lower than that detected in muscles from 'old' ATTP-KO mice. Similarly, the fold-inductions of two of the three cathepsins were also lower in 'adult' AT-deficient mice, as indicated by ≤ 1.6 -fold change, when compared to their inductions in 'old' mice (Table IV).

Collectively, these results show that AT-deficiency caused by either dietary depletion or by the deletion of ATTP-gene activates *sln*- and *uchl1*-gene clusters. The magnitude of these inductions was higher in 'old' mice compared to that in 'adult' mice.

Discussion

Transcriptomic programme for ataxic phenotype in skeletal muscles of ATTP-KO mice

The most significant and novel result of this study is the identification, by two independent analytical procedures, a robust induction of seven muscle genes, the *sln* cluster (Table IV),

whose simultaneous activation may contribute to age-related ataxia, defined by shorter stride-lengths of ATTP-KO mice compared to their WT-littermates [14,18]. The *sln* cluster of seven genes consisted of *sln*, *tnni*, *tnnc*, *tpm3*, *ATP2a2* (also known as *serca2a2*), *myh7* and *casq2*. Remarkably, five of these seven genes, *sln*, *tnni*, *tnnc*, *serca2a2* and *casq2*, encode proteins that are known to play an essential role in calcium mediated contraction–relaxation cycles of muscles [26,29,37]. The lack of co-ordinated induction of all these genes in younger, AT-deficient, mice (Table IV) which were asymptomatic prompt the interpretation that the sarcolipin cluster of ‘old’ ATTP-KO mice may be associated with the neuromuscular deficits observed in mice with severe AT-deficiency [14,18].

Of the seven genes in the sarcolipin gene cluster, *sln* showed a > 14-fold induction; the highest induction in this group, and it was independently confirmed by qRT-PCR of RNA extracts from nine different muscle samples (Table IV). Additional confirmation of *sln* induction by AT-deficiency was also obtained by qRT-PCR data from muscles of younger ATTP-KO mice and from muscles of WT mice fed an AT-depleted diet (Table IV). Previously mice displaying myopathy showed a > 70-fold induction of *sln* in response to the deletion of nebulin-gene [38]. *sln* encodes a 3.1 kDa protein that inhibits the activity of SERCA2, a Ca^{++} pump that actively removes Ca^{++} from sarcoplasm and participates in the recovery of muscle from contraction [27]. Hence, over-expression of *sln* detected in muscles of AT-deficient mice may delay muscle recovery from contraction. The muscles of ~10-month old, AT-deficient rats also displayed abnormal electromyographic properties [39], possibly due to over-expression of *sln*. This postulate is further reinforced by the observations that the forced over-expression of *sln* in rat soleus muscle inhibits SERCA, decreases luminal Ca^{++} and impairs contractility [40]. Our preliminary electrophysiological experiments that assayed isometric contractions of gastrocnemius muscle group via sciatic nerve stimulation showed that muscles from a 1-year old ATTP-KO mouse failed to maintain tetanic force and failed to recover after titanic stimulation when compared to the muscle of a 1-year old WT mouse (Carlsen and Bodine, unpublished). Further electrophysiological experiments are necessary to validate these preliminary observations and to further distinguish between the contribution of motor units and muscle fibre functions.

Two previous studies have suggested co-regulation of SLN and SERCA [26,41]. The data in Tables II–IV suggest that the expressions of the two mRNAs are also co-regulated. Hence, the robust induction of *sln* and other members of sarcolipin gene cluster is a novel and unanticipated action of AT-deficiency in skeletal muscle and may contribute to the ataxic phenotype of the ATTP-KO mice. Further studies are necessary to assay the expression of SLN protein and its fibre-type distribution in ataxic muscles of ATTP-KO mice. Our preliminary studies with commercially available anti-SLN polyclonal antibody have been unsuccessful both in cardiac atria (positive control where SLN is abundantly expressed [26]) and in skeletal muscles of ATTP-KO mice. We note with interest that SLN was first detected as a protein that co-purified with SERCA1 from fast twitch skeletal muscle [42] and was identified as a proteolipid protein and designated ‘sarcolipin’ [43]. A lack of SLN protein induction in the presence of a large induction of mRNA would implicate a role for micro RNA(s) which are known to block protein synthesis [44,45]. Experimental evaluations of these possibilities remain major challenges in addressing the molecular basis of AT-sensitive neuromuscular functions.

The large induction of *sln* was accompanied by the co-inductions of *tnni*, *tnnc*, *tpm3* and *casq2* (Tables II, III – IV), all of which participate in regulating Ca^{++} dependent muscle contraction and relaxation cycles (Figure 2). Co-inductions of *tnni*, *tnnc* and *tpm3* may be consistent with the observation that TNNI, TNNC and TPM3 form an inhibitory unit that prevents the interactions between actin and myosin [29]. Tables II–IV also show induction of the gene that encodes *casq2*, the main Ca^{++} buffer of sarcoplasmic reticulum [28]. A previous study has shown that over-expression of *casq2* in cardiac muscle decreases contractility [46].

Therefore, over-expression of these four genes may further add to the inhibitory actions of *sln* over-expression on skeletal muscle contractility of ATTP-KO mice. Future studies are necessary to determine if the changes in mRNAs detected here are translated into the respective proteins and if all the members of the sarcolipin gene cluster are necessary to display short-stride lengths of the old, ATTP-KO mice. Our data (Table IV) from 'adult', 8-month old, asymptomatic, AT-deficient mice suggest that the co-inductions of all the genes within the sarcolipin gene cluster may be required for the display of shorter stride lengths of ATTP-KO mice compared to those of their WT-littermates.

The only previous skeletal muscle study of chronic (up to ~13 months) vitamin E deficiency in rats that used GeneChips identified 56 AT-sensitive genes, all of which were induced by dietary vitamin E deficiency [21]. Hence, two studies that used different *in vivo* models to produce AT-deficient muscles and different data analysis protocols arrived at very similar numbers of AT-sensitive genes. There is also a considerable overlap in the functional groups of genes that are modulated by severe AT-deficiency. The induction of the cluster of genes that encode vesicular and secretory function (Table II) is also noteworthy because two previous studies have documented a role for AT in the modulation of genes that regulate vesicle assembly and function [12,47]. Comparison of the muscle AT-sensitive genes in the two studies gives important clues about the genes that may contribute to the ataxic phenotype of vitamin E deficient rodents and, possibly, humans. The data from dietary AT-deficient rats [21] were remarkable for the lack of change in the sarcolipin gene cluster described in this study (Tables II, III and IV). It is also noted that the rats were asymptomatic. This observation underscores the possible relevance of the sarcolipin gene cluster in the delayed display of ataxia in the mouse model of AVED [14,18].

AT-sensitive changes in the cerebral cortex may also contribute to the ataxia phenotype of AT-deficient mice [12,14] and neurological deficits of AT-deficient rats [48]. Previous studies in rodents [49] and humans [50] have suggested that chronic AT-deficiency results in initial loss of neural functions. Hence, the transcriptomic responses of skeletal muscles of ATTP-KO mice described here may be in addition to neural deficits. Further studies that address the changes in gene expression programmes of the various regions of the central nervous system, the peripheral nervous system and the muscular system are needed to characterize the chronology of molecular changes that are associated with the emergence of neuromuscular phenotypes associated with chronic AT-deficiency.

AT-deficiency activates protein degradation and inflammation pathways

Muscles of ATTP-KO mice had increased expression of genes that encode proteolytic enzymes associated with lysosomes and phagosomes and members of proteosomal pathway (Tables II, III and IV). Presence of increased levels of lysosomes in muscles of an AT-deficient patient have also been described [11]. The induction of cathepsins (Tables II, III and IV) was also reported in the previous study [21]. Unlike the previous study, the present study detected over-expression of CD36 gene (Tables II, III and III), which encodes the receptor for oxidized lipoproteins [51,52], in 'old' but not in 'adult' AT-deficient mice. Since the induction of CD36 was detected only in the 'old' ataxic mice we infer that the inflammatory process is also a late event which may be triggered by increased accumulation of oxidized phospholipids [53] in AT-deficient muscles. Genes encoding apolipoproteins D and E genes were also activated by AT-deficiency (Table II). Products of these genes are often used as markers of increased inflammation [33,34] and have been reported to be induced in myopathies [54,55] that are not associated with AT-deficient muscles. Comparative analysis of muscle inflammatory markers associated with various myopathies may enable identification genes that are specifically associated with chronic AT-deficiency.

Temporal disconnect between the onset of AT-deficiency and the appearance of neuromuscular phenotypes

The molecular mechanisms that account for the long lag-phase (months) between the initiation of AT-deficiency and the display of neuromuscular phenotype remain unexplained. The phenomenon is extensively documented. For example, the maximum length of deficiency in the asymptomatic rats was 1-year post-weaning [21], which contrasts with almost 2 years of AT-deficiency, including the pre-weaning period, in ataxic, ATTP-KO mice.

It can be hypothesized that ‘pro-ataxic’ metabolites, yet to be identified, are generated and accumulate in terminally differentiated muscle fibres during chronic AT-deficiency. Since tocopherols are primarily sequestered in biological membranes [56], it is reasonable to propose that AT-depleted biological membranes, including nuclear membranes, are a significant source of these ‘pro-ataxic’ metabolites. Furthermore, phospholipids, a ubiquitous class of membrane lipids, are also present in the nucleoplasm [57] and have been suggested to be associated with, and modulate the activity of, chromatin [58]. Hence, AT-depleted muscle membranes may have altered phospholipid metabolism. The present GeneChip data may be interpreted to support this hypothesis. The assay identified a 2-fold induction of *cyp2e1* (Table II, Thiol oxidation and metabolic stress group). A previous study has suggested that AT inhibits CYP2E1 activity [59]. CYP2E1 has been suggested to increase reactive oxygen species [35, 36] which may affect activities of redox-sensitive transcription factors such as nuclear factor (erythroid-derived 2)-like 2 (NRF2), nuclear factor of kappa light polypeptide gene enhancer in B-cells, (NF- κ B) and hypoxia-inducible factor [60–62]. A previous transcriptomic analysis of lungs from ATTP-KO mice suggested modulation of AhR-NRF2-NF- κ B transcription factor networks [22]. A search of the muscle transcriptomic data (Table II) for genes that may be induced by the activation of these transcription factors identified genes such as diaphorase 1 (also known as NAD(P)H:menadione oxidoreductase), metallothionein 2, thioredoxin interacting protein and heat shock protein family, member 7 (Table II). The previous GeneChip analysis of AT-deficient muscles from rats fed AT-deficient diet for ~1-year also suggested increased expression of seven genes related to oxidative stress [21]. Collectively, these data offer mRNA correlates of metabolic pathways which may contribute to temporal changes in metabolites, possibly derived from lipids of membranes and nucleoplasm, which may result in an altered transcriptomic programme, precipitating failure of the neuromuscular functions with chronic AT-deficiency.

Conclusions

Comparative analysis of skeletal muscle transcriptomes from ‘old’, 23-month, ataxic, ATTP-KO mice and their WT-littermates identified two genes, *sln* and *uchl1*, as sensitive responders of AT-deficiency. *Sln* encodes a ~3.2 kDa proteolipid protein that is an inhibitor of sarcoplasmic reticulum calcium transporting ATPase and it regulates relaxation-contraction cycles. Furthermore, six additional genes whose encoded proteins participate in relaxation-contraction cycle were also over-expressed in ataxic muscles. Hence, these seven co-regulated genes appear to form a functional cluster, ‘the sarcolipin gene cluster’, which may contribute to delayed ataxia in α -tocopherol-transfer protein deficient mice and possibly in AVED patients. These transcriptomic data suggest a role for α -tocopherol in the transcriptional regulation of genes that affect calcium dynamics across sarcoplasmic reticulum.

Acknowledgments

We thank Professor Maret Traber (Linus Pauling Institute, Oregon State University) for her valuable comments and suggestions in the preparation of this manuscript. We also thank Professor Jerry Last for his generous gift of Mouse Genome Affymetrix arrays. The research was funded by the following agencies: NIH Grant #ES011985, USDA grant # 35200-13456, University of California Clinical Nutrition Research Unit and University of California, Davis, Center for Human Nutrition Research Pilot Research Grant.

References

1. Morley S, Cacchini M, Zhang W, Virgulti A, Noy N, Atkinson J, Manor D. Mechanisms of ligand transfer by the hepatic tocopherol transfer protein. *J Biol Chem* 2008;283:17797–17804. [PubMed: 18458085]
2. Sato Y, Arai H, Miyata A, Tokita S, Yamamoto K, Tanabe T, Inoue K. Primary structure of alpha-tocopherol transfer protein from rat liver. Homology with cellular retinaldehyde-binding protein. *J Biol Chem* 1993;268:17705–17710. [PubMed: 8349655]
3. Sato Y, Hagiwara K, Arai H, Inoue K. Purification and characterization of the alpha-tocopherol transfer protein from rat liver. *FEBS Lett* 1991;288:41–45. [PubMed: 1879562]
4. Arita M, Sato Y, Miyata A, Tanabe T, Takahashi E, Kayden HJ, Arai H, Inoue K. Human alpha-tocopherol transfer protein: cDNA cloning, expression and chromosomal localization. *Biochem J* 1995;306:437–443. [PubMed: 7887897]
5. Gohil K, Oommen S, Quach HT, Vasu VT, Aung HH, Schock B, Cross CE, Vatassery GT. Mice lacking alpha-tocopherol transfer protein gene have severe alpha-tocopherol deficiency in multiple regions of the central nervous system. *Brain Res* 2008;1201:167–176. [PubMed: 18299118]
6. Manor D, Morley S. The alpha-tocopherol transfer protein. *Vitam Horm* 2007;76:45–65. [PubMed: 17628171]
7. Traber MG. Vitamin E regulatory mechanisms. *Annu Rev Nutr* 2007;27:347–362. [PubMed: 17439363]
8. Gotoda T, Arita M, Arai H, Inoue K, Yokota T, Fukuo Y, Yazaki Y, Yamada N. Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein. *N Engl J Med* 1995;333:1313–1318. [PubMed: 7566022]
9. Ouahchi K, Arita M, Kayden H, Hentati F, Ben Hamida M, Sokol R, Arai H, Inoue K, Mandel JL, Koenig M. Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. *Nat Genet* 1995;9:141–145. [PubMed: 7719340]
10. Kayden HJ. Tocopherol content of adipose tissue from vitamin E-deficient humans. *Ciba Found Symp* 1983;101:70–91. [PubMed: 6360590]
11. Guggenheim MA, Ringel SP, Silverman A, Grabert BE, Neville HE. Progressive neuromuscular disease in children with chronic cholestasis and vitamin E deficiency: clinical and muscle biopsy findings and treatment with alpha-tocopherol. *Ann NY Acad Sci* 1982;393:84–95. [PubMed: 6959572]
12. Gohil K, Schock BC, Chakraborty AA, Terasawa Y, Raber J, Farese RV Jr, Packer L, Cross CE, Traber MG. Gene expression profile of oxidant stress and neurodegeneration in transgenic mice deficient in alpha-tocopherol transfer protein. *Free Radic Biol Med* 2003;35:1343–1354. [PubMed: 14642382]
13. Terasawa Y, Ladha Z, Leonard SW, Morrow JD, Newland D, Sanan D, Packer L, Traber MG, Farese RV Jr. Increased atherosclerosis in hyperlipidemic mice deficient in alpha-tocopherol transfer protein and vitamin E. *Proc Natl Acad Sci USA* 2000;97:13830–13834. [PubMed: 11095717]
14. Yokota T, Igarashi K, Uchihara T, Jishage K, Tomita H, Inaba A, Li Y, Arita M, Suzuki H, Mizusawa H, Arai H. Delayed-onset ataxia in mice lacking alpha-tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. *Proc Natl Acad Sci USA* 2001;98:15185–15190. [PubMed: 11752462]
15. Cuddihy SL, Ali SS, Musiek ES, Lucero J, Kopp SJ, Morrow JD, Dugan LL. Prolonged alpha-tocopherol deficiency decreases oxidative stress and unmasks alpha-tocopherol-dependent regulation of mitochondrial function in the brain. *J Biol Chem* 2008;283:6915–6924. [PubMed: 18180306]
16. Nishida Y, Yokota T, Takahashi T, Uchihara T, Jishage K, Mizusawa H. Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. *Biochem Biophys Res Commun* 2006;350:530–536. [PubMed: 17026966]
17. Ren YR, Nishida Y, Yoshimi K, Yasuda T, Jishage K, Uchihara T, Yokota T, Mizuno Y, Mochizuki H. Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain. *J Neurochem* 2006;98:1810–1816. [PubMed: 16787402]

18. Gohil K, Godzdzanker R, O'Roark E, Schock BC, Kaini RR, Packer L, Cross CE, Traber MG. Alpha-tocopherol transfer protein deficiency in mice causes multi-organ deregulation of gene networks and behavioral deficits with age. *Ann NY Acad Sci* 2004;1031:109–126. [PubMed: 15753139]
19. Leonard SW, Terasawa Y, Farese RV Jr, Traber MG. Incorporation of deuterated RRR- or all-rac-alpha-tocopherol in plasma and tissues of alpha-tocopherol transfer protein-null mice. *Am J Clin Nutr* 2002;75:555–560. [PubMed: 11864863]
20. Thomas PK, Cooper JM, King RH, Workman JM, Schapira AH, Goss-Sampson MA, Muller DP. Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function. *J Anat* 1993;183:451–461. [PubMed: 8300427]
21. Nier B, Weinberg PD, Rimbach G, Stocklin E, Barella L. Differential gene expression in skeletal muscle of rats with vitamin E deficiency. *IUBMB Life* 2006;58:540–548. [PubMed: 17002982]
22. Gohil K, Oommen S, Vasu VT, Aung HH, Cross CE. Tocopherol transfer protein deficiency modifies nuclear receptor transcriptional networks in lungs: modulation by cigarette smoke *in vivo*. *Mol Aspects Med* 2007;28:453–480. [PubMed: 17400288]
23. Oommen S, Vasu VT, Leonard SW, Traber MG, Cross CE, Gohil K. Genome wide responses of murine lungs to dietary alpha-tocopherol. *Free Radic Res* 2007;41:98–109. [PubMed: 17164183]
24. Vasu VT, Hobson B, Gohil K, Cross CE. Genome-wide screening of alpha-tocopherol sensitive genes in heart tissue from alpha-tocopherol transfer protein null mice (ATTP(-/-)). *FEBS Lett* 2007;581:1572–1578. [PubMed: 17382327]
25. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. *Proc Natl Acad Sci USA* 2001;98:31–36. [PubMed: 11134512]
26. Babu GJ, Bhupathy P, Carnes CA, Billman GE, Periasamy M. Differential expression of sarcolipin protein during muscle development and cardiac pathophysiology. *J Mol Cell Cardiol* 2007;43:215–222. [PubMed: 17561107]
27. Bhupathy P, Babu GJ, Periasamy M. Sarcolipin and phospholamban as regulators of cardiac sarcoplasmic reticulum Ca²⁺ ATPase. *J Mol Cell Cardiol* 2007;42:903–911. [PubMed: 17442337]
28. Reyes-Juarez JL, Juarez-Rubi R, Rodriguez G, Zarain-Herzberg A. Transcriptional analysis of the human cardiac calsequestrin gene in cardiac and skeletal myocytes. *J Biol Chem* 2007;282:35554–35563. [PubMed: 17938175]
29. Galinska-Rakoczy A, Engel P, Xu C, Jung H, Craig R, Tobacman LS, Lehman W. Structural basis for the regulation of muscle contraction by troponin and tropomyosin. *J Mol Biol* 2008;379:929–935. [PubMed: 18514658]
30. Bechet D, Tassa A, Taillandier D, Combaret L, Attaix D. Lysosomal proteolysis in skeletal muscle. *Int J Biochem Cell Biol* 2005;37:2098–2114. [PubMed: 16125113]
31. Houde M, Bertholet S, Gagnon E, Brunet S, Goyette G, Laplante A, Princiotta MF, Thibault P, Sacks D, Desjardins M. Phagosomes are competent organelles for antigen cross-presentation. *Nature* 2003;425:402–406. [PubMed: 14508490]
32. Loureiro J, Ploegh HL. Antigen presentation and the ubiquitin-proteasome system in host-pathogen interactions. *Adv Immunol* 2006;92:225–305. [PubMed: 17145306]
33. Kim E, Tolhurst AT, Qin LY, Chen XY, Febbraio M, Cho S. CD36/fatty acid translocase, an inflammatory mediator, is involved in hyperlipidemia-induced exacerbation in ischemic brain injury. *J Neurosci* 2008;28:4661–4670. [PubMed: 18448643]
34. Teupser D, Mueller MA, Koglin J, Wilfert W, Ernst J, von Scheidt W, Steinbeck G, Seidel D, Thiery J. CD36 mRNA expression is increased in CD14⁺ monocytes of patients with coronary heart disease. *Clin Exp Pharmacol Physiol* 2008;35:552–556. [PubMed: 18067591]
35. Goasduff T, Cederbaum AI. NADPH-dependent microsomal electron transfer increases degradation of CYP2E1 by the proteasome complex: role of reactive oxygen species. *Arch Biochem Biophys* 1999;370:258–270. [PubMed: 10510285]
36. Lu Y, Cederbaum AI. CYP2E1 and oxidative liver injury by alcohol. *Free Radic Biol Med* 2008;44:723–738. [PubMed: 18078827]
37. Beard NA, Wei L, Cheung SN, Kimura T, Varsanyi M, Dulhunty AF. Phosphorylation of skeletal muscle calsequestrin enhances its Ca(2+) binding capacity and promotes its association with junctin. *Cell Calcium* 2008;44:363–373. [PubMed: 19230141]

38. Ottenheijm CA, Fong C, Vangheluwe P, Wuytack F, Babu GJ, Periasamy M, Witt CC, Labeit S, Granzier H. Sarcoplasmic reticulum calcium uptake and speed of relaxation are depressed in nebulin-free skeletal muscle. *Faseb J* 2008;22:2912–2919. [PubMed: 18434434]
39. Goss-Sampson MA, Kriss A, Muddle JR, Thomas PK, Muller DP. Lumbar and cortical somatosensory evoked potentials in rats with vitamin E deficiency. *J Neurol Neurosurg Psychiatry* 1988;51:432–435. [PubMed: 2834520]
40. Tupling AR, Asahi M, MacLennan DH. Sarcolipin over-expression in rat slow twitch muscle inhibits sarcoplasmic reticulum Ca²⁺ uptake and impairs contractile function. *J Biol Chem* 2002;277:44740–44746. [PubMed: 12237298]
41. Vangheluwe P, Schuermans M, Zador E, Waelkens E, Raeymaekers L, Wuytack F. Sarcolipin and phospholamban mRNA and protein expression in cardiac and skeletal muscle of different species. *Biochem J* 2005;389:151–159. [PubMed: 15801907]
42. MacLennan DH, Yip CC, Iles GH, Seeman P. Isolation of sarcoplasmic reticulum proteins. *Cold Spring Harbor Symp Quant Biol* 1972;37:469–478.
43. Wawrzynow A, Theibert JL, Murphy C, Jona I, Martonosi A, Collins JH. Sarcolipin, the ‘proteolipid’ of skeletal muscle sarcoplasmic reticulum, is a unique, amphipathic, 31-residue peptide. *Arch Biochem Biophys* 1992;298:620–623. [PubMed: 1416990]
44. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. The impact of microRNAs on protein output. *Nature* 2008;455:64–71. [PubMed: 18668037]
45. Selbach M, Schwanhauser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. *Nature* 2008;455:58–63. [PubMed: 18668040]
46. Sato Y, Ferguson DG, Sako H, Dorn GW 2nd, Kadambi VJ, Yatani A, Hoit BD, Walsh RA, Kranias EG. Cardiac-specific overexpression of mouse cardiac calsequestrin is associated with depressed cardiovascular function and hypertrophy in transgenic mice. *J Biol Chem* 1998;273:28470–28477. [PubMed: 9774476]
47. Nell S, Bahtz R, Bossecker A, Kipp A, Landes N, Bumke-Vogt C, Halligan E, Lunec J, Brigelius-Flohe R. PCR-verified microarray analysis and functional in vitro studies indicate a role of alphatocopherol in vesicular transport. *Free Radic Res* 2007;41:930–942. [PubMed: 17654050]
48. Hyland S, Muller D, Hayton S, Stoecklin E, Barella L. Cortical gene expression in the vitamin E-deficient rat: possible mechanisms for the electrophysiological abnormalities of visual and neural function. *Ann Nutr Metab* 2006;50:433–441. [PubMed: 16847396]
49. Hayton SM, Kriss T, Wade A, Muller DP. Effects on neural function of repleting vitamin E-deficient rats with alphatocopherol. *J Neurophysiol* 2006;95:2553–2559. [PubMed: 16394074]
50. Sokol RJ, Bove KE, Heubi JE, Iannaccone ST. Vitamin E deficiency during chronic childhood cholestasis: presence of sural nerve lesion prior to 2 1/2 years of age. *J Pediatr* 1983;103:197–204. [PubMed: 6308196]
51. Endemann G, Stanton LW, Madden KS, Bryant CM, White RT, Protter AA. CD36 is a receptor for oxidized low density lipoprotein. *J Biol Chem* 1993;268:11811–11816. [PubMed: 7685021]
52. Luangrath V, Brodeur MR, Rhainds D, Brissette L. Mouse CD36 has opposite effects on LDL and oxidized LDL metabolism *in vivo*. *Arterioscler Thromb Vasc Biol* 2008;28:1290–1295. [PubMed: 18436808]
53. Hazen SL. Oxidized phospholipids as endogenous pattern recognition ligands in innate immunity. *J Biol Chem* 2008;283:15527–15531. [PubMed: 18285328]
54. Haslett JN, Kunkel LM. Microarray analysis of normal and dystrophic skeletal muscle. *Int J Dev Neurosci* 2002;20:359–365. [PubMed: 12175874]
55. Zhou X, Dimachkie MM, Xiong M, Tan FK, Arnett FC. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. *Med Sci Monit* 2004;10:BR191–BR197. [PubMed: 15232492]
56. Atkinson J, Epand RF, Epand RM. Tocopherols and tocotrienols in membranes: a critical review. *Free Radic Biol Med* 2008;44:739–764. [PubMed: 18160049]
57. Hunt AN. Completing the cycles; the dynamics of endonuclear lipidomics. *Biochim Biophys Acta* 2006;1761:577–587. [PubMed: 16581290]
58. Albi E, Lazzarini R, Viola Magni M. Phosphatidylcholine/sphingomyelin metabolism crosstalk inside the nucleus. *Biochem J* 2008;410:381–389. [PubMed: 18001268]

59. Caro AA, Cederbaum AI. Role of intracellular calcium and phospholipase A2 in arachidonic acid-induced toxicity in liver cells overexpressing CYP2E1. *Arch Biochem Biophys* 2007;457:252–263. [PubMed: 17118330]
60. Gorlach A, Bonello S. The cross-talk between NF-kappaB and HIF-1: further evidence for a significant liaison. *Biochem J* 2008;412:e17–e19. [PubMed: 18498249]
61. Ji LL. Modulation of skeletal muscle antioxidant defense by exercise: role of redox signaling. *Free Radic Biol Med* 2008;44:142–152. [PubMed: 18191750]
62. Chen XL, Dodd G, Thomas S, Zhang X, Wasserman MA, Rovin BH, Kunsch C. Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression. *Am J Physiol Heart Circ Physiol* 2006;290:H1862–H1870. [PubMed: 16339837]

Figure 1.

α -TTP mRNA (ATTP) expression in muscles and livers of 2-year old wild type (WT) and α -tocopherol transfer protein deficient (KO) mice. ATTP and GAPDH mRNA expressions were assayed by GeneChips and qRT-PCR. The GeneChip data are from muscles of WT ($n=2$) and ATTP-KO ($n=2$) mice. The qRT-PCR data were normalized to GAPDH expression in each sample. ATTP expression in KO-liver was very low ($p < 0.00001$) and it was undetectable in muscles. The qRT-PCR data are mean $\pm$ SEM, for five WT and four KO tissues.

Figure 2.

Schematic representation of proteins that participate in calcium-dependent regulation of muscle contraction-relaxation cycles. Calcium is stored, bound to calsequestrin, in the lumen of sarcoplasmic reticulum. It is released, through ryanodine receptors, into the sarcoplasm in response to a nerve stimulus, causing muscle contraction. To initiate relaxation, Ca^{++} is pumped out by SERCA2. Activity of SERCA2 is inhibited by SLN and PLN. Genes encoding proteins (shades of green or grey, darker=higher expression) were over-expressed in ataxic muscles of 2-year old male, ATTP-KO mice compared to those in age-matched, male WT-mice. The numbers indicate fold-induction of the mRNA, obtained by qRT-PCR, in the ATTP-KO muscles. ■ sarcolipin (SLN), ●● troponin I and troponin c, ● tropomyosin, ⌈ phospholamban (PLN), ■ sarco-endoplasmic reticulum calcium ATPase2 (SERCA2), ● calsequestrin, ⌘⌘⌘ myosin of thick filament, ○ ryanodine receptor.

Table I

List of genes selected from GeneChip data and subjected to qRT-PCR validation. The specific primer pairs [deoxynucleotide sequences (5' to 3') are shown for each primer] for each gene. The oligonucleotide sequences from Affymetrix probeset identifiers were used to design primers of the respective genes using the primer design software. The primers were custom prepared and used as described in the Materials and methods section.

Gene name	Forward primer	Reverse primer
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	GTGGCCAGATTGCTCTACAGTG	AGGGCCCATTAGAAAGCATGT
B cell leukaemia/lymphoma 6	GAAGTTTTCAATGATGGACGGG	GCCTACACTTCAAAAAGGGATGG
CD36 antigen	GAAAATCAAGCTCCTTGGCATG	ACTCCAATCCCAAGTAAGGCC
Cathepsin B	GAACCACTGTGGCATTGAATCA	TCAGTGCGTGGGATTCCAG
Cathepsin L	ACCACTGTGGACTTGCCACC	CCCATCAATTCACGACAGGAT
Cathepsin S	GACGACCCCTCCTGTACGG	GCCAACCACAAGAACACCATG
Glyceraldehyde-3-phosphate dehydrogenase	TTGTGGAAGGGCTCATGACC	TCTTCTGGGTGGCAGTGATG
Sarcoplipin	TGTGCCCTGCTCCTCTTC	TGATTGCACACCAAGGCTTG
Troponin C, cardiac/slow skeletal	GAAGGACGACAGCAAAGGGA	CGGAAGAGATCCGACAGCTC
Troponin I, skeletal, slow I	CAGCCTATGCGCACACCTTT	TCCCCTTTGTGTGCCATTTC
Ubiquitin carboxy-terminal hydrolase L1	ACGGCCATCTGTACGAGCTC	CATGGTTCACTGGAAGGGC
α -tocopherol transfer protein	TGGAACTCAACGCAATGGAG	GCCAGCCTTCCAGGTCAA

Table II

α -tocopherol sensitive genes in muscles of 23-month old ataxic, male mice. Gene expression data from WT muscles ($n=2$ mice) were used as baseline and those from ATTP-KO muscles ($n=2$ mice) were used as experimental to calculate fold-change by dChip data analysis software for Affymetrix arrays. The data were grouped according to function from the list of 57 genes that were differentially expressed.

Functional group and gene name	Fold changeprobe set ID	Accession #
<i>Cytoskeletal and Ca sensitive</i>		
sarcolipin	14.71420884_at	AK008863
periostin, osteoblast-specific factor	6.51423606_at	BI110565
PDZ and LIM domain 5	3.71421413_a_at	NM_022554
tropoinin I, skeletal, slow 1	3.61450813_a_at	NM_021467
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2	3.51452363_a_at	AA245637
tropomyosin 3, gamma	3.41449996_a_at	NM_022314
tropoinin C, cardiac/slow skeletal	2.81418370_at	NM_009393
myosin, heavy polypeptide 7, cardiac muscle, beta	2.71448553_at	NM_080728
capping protein (actin filament) muscle Z-line, beta	2.61453960_a_at	AK007209
vimentin	2.31450641_at	M24849
matrix Gla protein	2.21448416_at	NM_008597
calsequestrin 2	2.01422529_s_at	NM_009814
<i>Protein degradation</i>		
ubiquitin carboxy-terminal hydrolase L1	8.41448260_at	NM_011670
cathepsin S	6.21448591_at	NM_021281
lysozyme	4.11423547_at	AW208566
P lysozyme structural	3.61436996_x_at	AV066625
cathepsin B	3.31448732_at	M14222
proteasome (prosome, macropain) 26S sub-unit, non-ATPase	2.41451056_at	BB034143
ubiquitin-conjugating enzyme E2D 3 (UBC4/5 homologue, yeast)	2.31455480_s_at	BG070759
cathepsin L	2.11451310_a_at	J02583
lysosomal-associated protein transmembrane 4A	2.01423368_at	BI695636
<i>Immune-inflammation</i>		
immunoglobulin kappa chain, constant region	5.71452417_x_at	AV057155
lectin, galactose binding, soluble 3	4.41426808_at	X16834
apolipoprotein E	2.91432466_a_at	AK019319
beta-2 microglobulin	2.71452428_a_at	AI099111
CD36 antigen	2.31450883_a_at	BB534670
apolipoprotein D	2.31416371_at	NM_007470
histocompatibility 2, D region	2.21451784_x_at	L36068
histocompatibility 2, class II antigen A, alpha	2.11435290_x_at	BE688749
<i>Thiol oxidation and metabolic stress</i>		
metallothionein 2	3.31428942_at	AA796766
cytochrome P450, family 2, sub-family e, polypeptide 1	3.21415994_at	NM_021282
thioredoxin interacting protein	3.21415997_at	AF173681
heat shock protein family, member 7 (cardiovascular)	2.81421290_at	BG968304
esterase D/formylglutathione hydrolase	2.11417825_at	NM_016903
cysteine and glycine-rich protein 3	2.11460318_at	NM_013808
spermine oxidase	-2.11424268_at	BC004831
<i>Vesicular and secretory</i>		
synaptophysin-like protein	3.01422879_at	BE333485
synaptopodin 2	2.91450828_at	NM_080451
reticulin 4	2.41421116_a_at	NM_024226
vesicle-associated membrane protein 3	-2.81437708_x_at	BB552111
<i>Mitochondrial</i>		
diaphorase 1 (NADH)	3.21422185_a_at	NM_029787
pyruvate dehydrogenase E1 alpha 1	2.61449137_at	NM_008810
indolethylamine N-methyltransferase	2.41418697_at	NM_009349
glutamate oxaloacetate transaminase 2, mitochondrial	2.31417716_at	U82470
<i>Miscellaneous</i>		
carbonic anhydrase 3	3.41460256_at	NM_007606
tumour differentially expressed 2	3.21454811_a_at	AV026664
ADP-ribosylation factor-like 6 interacting protein 2	3.21416794_at	NM_019717
neural precursor cell expressed, developmentally down-regulated gene 4	2.91451109_a_at	BG073415
glucan (1,4-alpha-), branching enzyme 1	2.21420654_a_at	NM_028803
protein phosphatase 3, catalytic sub-unit, beta isoform	2.21427468_at	M81483
integral membrane protein 2A	2.11451047_at	BI966443
musculoskeletal, embryonic nuclear protein 1	2.11427201_at	AJ277212
cell division cycle 42 homologue (S. cerevisiae)	2.11449574_a_at	BF143638
HESB like domain containing 2	2.11423652_at	AV209097
protein kinase inhibitor, alpha	2.01420858_at	AK010212
DEAD (Asp-Glu-Ala-Asp) box polypeptide 51	-2.01428728_at	AK010015
B-cell leukaemia/lymphoma 6	-2.31421818_at	U41465

Table III

Validation of GeneChip data by qRT-PCR assay. The genes selected from the list of 57 differentially expressed genes were analysed by qRT-PCR. Muscle RNA extracts from 'old', 23-month mice were used for validation. Four samples (two from WT mice and two from ATTP-KO mice) used for GeneChip assay and additional muscle RNA extracts from five mice (three WT mice and two ATTP-KO mice) were processed. The expression data from WT muscles were used as baseline and those from ATTP-KO muscles were used as experimental to calculate fold-changes as described in the Materials and methods section.

Gene name	symbol	Fold change (ATTP-KO/WT)	
		GeneChip (n=2)	qRT-PCR Mean±SEM (n=4-5)
sarcolipin	Sln	14.7	33.0±1.1
troponin C1	Tnnc1	2.8	4.8±0.4
troponin I	Tnni	3.6	2.3±0.4
calcium transporting ATPase	Atp2a2	2.0	3.4±0.5
protein kinase inhibitor, alpha	Pkia	2.0	1.7±0.4
ubiquitin carboxy-terminal hydroxylase L1	Uchl1	8.4	10.2±1.5
CD 36	CD36	2.3	3.3±0.8
cathepsin S	Ctss	6.2	3.0±0.3
cathepsin B	Ctsb	3.3	4.3±1.6
cathepsin L	Ctsl	2.1	1.4±0.4
B-cell leukemia/lymphoma 6	Bcl6	-2.3	-1.9 ± 0.3

Table IV

Changes in the expression of the *sarcolipin* and *ubiquitin carboxy-terminal hydrolase 1* gene clusters in skeletal muscles from 'adult', 8-month old, pre-ataxic and 'old', 23-month, ataxic mice. The expression of the seven genes of *sln* gene cluster and four genes of *uchl1* gene cluster was assayed by qRT-PCR of cDNA samples from skeletal muscles of 'adult', 8-month, mice fed either an AT-sufficient or an AT-depleted diet. Fold-change in the expression of the genes in the AT-depleted muscles was obtained by comparing its expression with that in the muscles of mice fed the AT-sufficient diet. Similarly, the effect of AT-deficiency imposed by the deletion of ATP gene were obtained by comparing the expression of the genes in 'adult', 8-month, AT-depleted muscles of ATP-KO mice with their WT-littermates.

Gene name	Genotype Age Diet symbol	Fold change determined by qRT-PCR		
		WT	KO	KO
		8-month DEFICIENT Mean±SEM (n=3-5)	8-month NORMAL Mean±SEM (n=3-5)	23-month NORMAL Mean±SEM (n=4-5)
sarcolipin	Sln	11.3±2.3	6.7±1.8	33.0±1.1
troponin C1	Tnnc1	1.3±0.3	1.4±0.4	4.8±0.4
troponin I1	Tnni1	3.6±0.6	1.5±0.2	2.3±0.4
calcium transporting ATPase	Atp2a2	3.1±0.5	-1.2±0.7	3.4±0.5
calsequestrin 2	Casq2	1.1±0.2	1.5±0.3	1.7±0.4
tropomyosin 3, gamma	Tpm3	1.1±0.2	1.8±0.4	3.3±0.9
myosin, heavy polypeptide 7	Myh7	-1.5 ± 0.6	1.1±0.2	1.5±0.2
ubiquitin carboxy-terminal hydroxylase L1	Uchl1	4.2±1.0	7.6±0.5	10.2±1.5
cathepsin S	Ctss	4.1±0.8	1.9±0.2	3.0±0.3
cathepsin B	Ctsb	1.6±0.2	1.3±0.1	4.3±1.6
cathepsin L	Ctsl	1.0±0.2	-1.5±0.8	1.4±0.4
		pre-ataxic		ataxic